Text Box: MYCOPHENOLATE MOFETIL THERAPY FOR CHILDREN LUPUS NEPHRITIS REFRACTORY TO BOTH INTRAVENOUS CYCLOSPHOSPHAMIDE AND CYCLOSPORINE Fu YF, Liu GL Department of Pediatrics, Nanjing JinLing Hospital, Nanjing, China Objective: To find an effective therapy method for lupus nephritis refractory to both intravenous cyclosphosphamide and cyclosporine. Methods: MMF20-25mg/kg.d with low dose of prednisone (5-7.5 mg/d) was given to 2 patients with lupus nephritis refractory to both intravenous cyclosphosphamide and cyclosporine. Results: All systemic symptoms of lupus resolved, proteinuria decreased to very low levels, most of autoantibodies (antinuclear, anti-dsDNA, anti-Sm and anti-RNP) became negative, and remained clinically stable until now over 3 years. No adverse reactions including gastrointestinal [nausea and/or vomiting, diarrhea, gastritis, duodenitis and ulcers] or bone marrow suppressive [leukopenia, anemia and thrombocytopemia] was found during the period of MMF therapy. Conclusions: MMF may a promising therapy for lupus nephritis. 1003